Investment in Research and Development, Human Resources and Facilities to Expand the Business
First written in FY2020-Q3. 11 of 16 entries say "Restated". Latest entry: 2026-05-13.
63 other companies' latest entry also says "Advanced".
- FY2024-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥11.220 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥11.220 million for the cumulative second quarter. It explicitly stated that there were no material changes in the status of those activities. - FY2024-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥6.216 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥6.216 million for the cumulative first quarter. It stated that there were no material changes in the status of its R&D activities. - FY2023-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥20.285 million. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥20.285 million for the cumulative third quarter. It explicitly stated that there were no material changes in the status of its R&D activities. - FY2023-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥13.101 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥13.101 million for the cumulative second quarter. It stated that there were no material changes in the status of its R&D activities. - FY2023-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥7.855 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥7.855 million for the cumulative first quarter. It stated that there were no material changes in the status of its R&D activities. - FY2022AdvancedAnnual report
「Total capital expenditures during the fiscal year were ¥4.755 million. Major items included ¥1.860 million for the purchase of workstations, ¥678,000 for the purchase of server coolers, and ¥1.640 million in capital expenditures for the renewal of the investor relations website.」
The company made ¥4.755 million in capital expenditures during the period. It also presented a capital expenditure plan funded by the capital increase, comprising ¥50 million for development computers and equipment, ¥30 million for expanding the head office server room and other facilities, and ¥20 million for an internal management system. - FY2022-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥22.856 million. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥22.856 million for the cumulative third quarter. It explicitly stated that there were no material changes in the status of its R&D activities. - FY2022-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥14.798 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥14.798 million for the cumulative second quarter. It stated that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥6.831 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥6.831 million for the cumulative first quarter. It stated that there were no material changes in the status of its R&D activities. - FY2021-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥20.016 million. There were no material changes in the status of the company's R&D activities during the cumulative third quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥20.016 million for the cumulative third quarter. It explicitly stated that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥15.303 million. There were no material changes in the status of the company's R&D activities during the cumulative second quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥15.303 million for the cumulative quarter. It explicitly stated that there were no material changes in the status of those activities. - FY2021-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥10.148 million. There were no material changes in the status of the company's R&D activities during the cumulative first quarter.」
The company continued its R&D activities and disclosed R&D expenses of ¥10.148 million for the cumulative quarter. It stated that there were no material changes in the status of those activities. - FY2020AdvancedAnnual report
「Total capital expenditures during the fiscal year were ¥6.713 million. Major items included ¥4.748 million for the facilities of the Totsuka office, which opened on 1 October 2020, and ¥1.494 million for interior construction at the head office. These expenditures were financed mainly with funds from the capital increase.」
The company made ¥6.713 million in capital expenditures, including the opening of the Totsuka office, using funds from the capital increase. It also stated a policy of prioritizing ¥15.207 million in R&D expenses and retained earnings for R&D investment. - FY2020-Q3First statedAnnual report
「The funds are planned to be allocated to R&D expenses, recruitment and personnel expenses, and capital expenditures to secure the human resources and facilities needed for future business expansion and to acquire the company's own software technologies for next-generation AI processors.」
The planned uses of proceeds from the public offering include R&D, acquisition of software technologies for next-generation AI processors, recruitment and personnel expenses, and facilities.